Your browser doesn't support javascript.
loading
[Surgical management of gastric cancer in the era of immunotherapy].
Li, Z Y; Jia, Y N; Lu, X X; Guan, G M; Wang, Q.
Afiliación
  • Li ZY; Center of Gastrointestinal Tumors, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Jia YN; Center of Gastrointestinal Tumors, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Lu XX; Center of Gastrointestinal Tumors, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Guan GM; Center of Gastrointestinal Tumors, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Wang Q; Center of Gastrointestinal Tumors, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
Zhonghua Wai Ke Za Zhi ; 62(5): 353-358, 2024 May 01.
Article en Zh | MEDLINE | ID: mdl-38548601
ABSTRACT
With the widespread application of immune checkpoint inhibitors, chemotherapy combined with immunotherapy has shown promising efficacy in the treatment of various cancers. Especially gastric cancer, this strategy is gradually expanding from first-line treatment in advanced stages to perioperative management. Compared to neoadjuvant chemotherapy alone, the combined approach not only improves pathological regression but also leads to better downstaging, which is particularly significant in gastric cancer subsets that are HER2-positive, mismatch repair deficient, PD-L1 combined positive score ≥5, or EB virus-positive. This combined treatment has made it possible to reduce the extent of gastrectomy, perform function-preserving surgeries, or even consider non-surgical strategies. Currently, exploring the optimal protocols for combining immune checkpoint inhibitors with chemotherapy, identifying potential indications for function-preserving surgery, improving surgical methods, and developing non-surgical strategies represent key issues in the surgical management of gastric cancer in the era of immunotherapy.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Gastrectomía / Inmunoterapia Límite: Humans Idioma: Zh Revista: Zhonghua Wai Ke Za Zhi Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Gastrectomía / Inmunoterapia Límite: Humans Idioma: Zh Revista: Zhonghua Wai Ke Za Zhi Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: China